艾迪注射液联合三氧化二砷行肝动脉插管化疗栓塞治疗原发性肝癌临床疗效观察

目的]评价中药艾迪注射液联合三氧化二砷（As2O3）行肝动脉插管化疗栓塞（TACE）在原发性肝癌（HCC）患者中的临床治疗效果。方法]将80例HCC患者随机分为2组各40例,均接受超选择性TACE术。治疗组给予艾迪注射液100 ml加0.9%氯化钠500 ml静脉滴注（静滴）,d1~d21;静滴同时进行肝动脉介入治疗,药物为As2O3注射液10 mg;对照组采用常规化疗药物（5-氟尿嘧啶1 000 mg,顺铂50~70 mg,阿霉素40~50 mg,丝裂霉素8~16 mg）,经导管向供血动脉内注入碘油-化疗药物乳化剂,随后用明胶海绵（GS）或聚乙烯醇（PVA）微球栓塞该动脉。2组均4周为1个疗程,共治疗4个疗程。结果]治疗组40例中,完全缓解（CR）10例,部分缓解（PR）18例,无变化（SD）8例,恶化（PD）2例,死亡2例,总有效率为70.0%,甲胎蛋白（AFP）下降率为80.0%,肿瘤缩小率为77.5%,中位生存期为15个月。对照组40例中,CR 6例,PR 10例,SD 10例,PD 10例,死亡4例,总有效率为40.0%,AFP下降率为37.5%,肿瘤缩小率为55.0%,中位生存期为8.5个月。2组中度以上不良反应率分别为7.5%和35.0%。结论]艾迪注射液联合As2O3行TACE是一种安全、有效的治疗HCC的方法。

Clinical study of Aidi proinjection combined with arsenic trioxide by TACE in treating patients with primary liver cancer

Objective]To evaluate the clinical efficacy of Aidi(AD)proinjection combined with arsenic trioxide(As2O3)by transcatheter arterial chemoembolization(TACE)in treating primary liver cancer.Methods]Eighty patients with liver cancer receiving superselective TACE were retrospectively divided into two groups:treatment group and control group(each n=40).Patients in the treatment group were given intravenous AD injection(100 mL in 500 mL 0.9 %NaCl)for 21 days and As2O3 10mg by TACE;Patients in the control group r...